Newronika Strengthens Leadership with Appointment of Keith Carlton as Executive Chairman

Newronika Appoints Keith Carlton as Executive Chairman

In a significant move to bolster its strategic direction, Newronika, renowned for its trailblazing work in adaptive deep brain stimulation technology, has appointed Keith Carlton as the new Executive Chairman, effective immediately. Located in Milan, Italy, Newronika has positioned itself at the forefront of neuromodulation, aiming to transform how neurological disorders, particularly Parkinson's disease, are treated.

A Leader with Vision

Keith Carlton brings an impressive portfolio of executive leadership experience in the medical device and neuromodulation industries. His career is marked by a consistent track record of driving innovation, fostering strategic growth, and achieving operational excellence. This expertise makes him an optimal choice for guiding Newronika as it propels into a new phase of global expansion.

Lorenzo Rossi, Co-Founder and CEO of Newronika, expressed enthusiasm about Carlton's appointment, emphasizing, "We are honored to welcome Keith as our Executive Chairman. His strategic vision and demonstrated success in scaling medical technology companies significantly align with our goals to advance clinical validation and commercialization of AlphaDBS."

Transformative Technology on the Horizon

AlphaDBS is a proprietary adaptive deep brain stimulation system designed to offer precision therapy, enhancing symptom relief for Parkinson's disease patients while minimizing side effects. With Carlton at the helm, the company's emphasis on innovation will likely further establish Newronika's global presence and impact.

Carlo Sanfilippo, a Senior Investment Manager at Indaco Venture Partners and a member of the Newronika Board, shared his confidence in Carlton's capabilities, stating, "We warmly welcome Keith and trust in his extensive leadership experience to steer the company through its next growth stage."

Carlton expressed his eagerness to join Newronika during this transformative period, stating, "The company’s pioneering adaptive DBS technology holds the potential to redefine the standard of care for neurological disorders. I am looking forward to working with the Board and our talented team to accelerate innovation, enhance patient access, and create a global impact, particularly through the launch of the Phase III U.S. Pivotal trial."

Recent Milestones Solidify Future Goals

Carlton’s appointment reflects Newronika's commitment to reinforcing its leadership foundation amidst notable recent milestones. These include receiving CE Mark approval for AlphaDBS, obtaining U.S. FDA IDE clearance, and successfully securing €13.6 million in Series B financing. Together, these achievements underscore Newronika's dedication to instigating a paradigm shift in neuromodulation therapies globally.

Newronika, a spin-off from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan, is transforming deep brain stimulation through its advanced adaptive technology, which leverages real-time neurophysiological feedback to optimize therapy. With ongoing regulatory approvals and clinical initiatives in Europe, the U.S., and beyond, Newronika aims to continuously advance the field of adaptive DBS.

In summary, the appointment of Keith Carlton as Executive Chairman heralds a new era for Newronika. With his strategic leadership, the company is poised to enhance its mission of improving patient care and extending its innovative solutions to a broader audience while remaining focused on clinical validation and commercialization of its cutting-edge technology.

About Newronika SpA

Newronika is committed to advancing adaptive deep brain stimulation technology by pushing the boundaries of traditional approaches in treating neurological disorders. The company’s headquarters in Milan demonstrate its commitment to fostering innovation and collaboration among leading healthcare professionals. Under Keith Carlton's stewardship, Newronika's trajectory in the medical technology landscape is sure to evolve, setting the stage for groundbreaking developments in patient care and treatment success.

For more information, visit Newronika's official website.